Genuair®/Pressair® Inhaler in the Treatment of COPD – Minimum Errors During Inhalation and High Patient Satisfaction
The article by German authors summarizes the results achieved with the Genuair® inhaler (marketed in the USA under the name Pressair®), highlighting its ease of use, simple patient training, low error rates during inhalation compared to other inhalers, and high patient satisfaction and willingness to continue treatment.
Simple and Safe Use
Genuair® is a breath-actuated dry powder inhaler designed for the administration of aclidinium or the combination of aclidinium with formoterol for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). The two-step inhalation process reduces the likelihood of errors when handling the inhaler.
The device is equipped with several mechanisms that simplify its use and enhance safety. These include a safety mechanism that prevents the release of a second dose, a mechanism that locks the inhaler after the last dose, and both visual and auditory signals that facilitate the correct dose administration.
The success of inhalation is a significant factor affecting the effectiveness of treatment. Clinical studies have shown that the Genuair® inhaler is easy to use, requires less training time for patients, and results in fewer errors (including critical ones) than other compared devices.
Satisfaction with Treatment
Several randomized crossover studies have also demonstrated higher patient satisfaction with the Genuair® inhaler among COPD patients, their willingness to continue treatment, and a preference for this device over other inhalers. The results show satisfaction among various patient populations, including older individuals and those with limited airflow. Since patient preference and satisfaction are closely related to adherence to COPD treatment, the results found with the Genuair® inhaler could mean higher treatment adherence and, consequently, better effectiveness.
Conclusion
The choice of inhaler is an important aspect of COPD treatment. When choosing, it is always necessary to consider patient characteristics such as age, ability to properly use the device, breathing capacity, whether the patient is right-handed or left-handed, and their preferences. The ease of use, safety mechanisms, and satisfaction demonstrated with the Genuair® inhaler may influence treatment adherence and its effectiveness.
(zza)
Source: Magnussen H., Fyrnys B., Greguletz R. Genuair®/Pressair® inhaler in COPD: the patient perspective. COPD 2019; 16 (2): 196−205, doi: 10.1080/15412555.2019.1630807.
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
